1-溴-4-(4-乙氧基苯基)苯 | 58743-80-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-溴-4-(4-乙氧基苯基)苯
• 英文名称: ethyl 4-(4-bromophenyl)-phenyl ether
• 英文别名: 1-bromo-4-(4-ethoxyphenyl)benzene；4-bromo-4'-ethoxylbiphenyl；4-bromo-4'-ethoxybiphenyl；ethyl-(4'-bromo-biphenyl-4-yl)-ether；Aethyl-(4'-brom-biphenyl-4-yl)-aether；ethyl 4-(4-bromophenyl) phenyl ether；1-(4-Bromophenyl)-4-ethoxybenzene
• CAS: 58743-80-9
• 化学式: C₁₄H₁₃BrO
• 分子量: 277.161
• InChiKey: KTNZDANAUJJRBF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2909309090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-(4-Bromophenyl)-4-ethoxybenzene
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-(4-Bromophenyl)-4-ethoxybenzene
CAS number: 58743-80-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C14H13BrO
Molecular weight: 277.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-溴-4-(4-乙氧基苯基)苯 在 正丁基锂 、 硼酸三甲酯 、 盐酸 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 生成 4-乙氧基二苯基-4-硼酸
  参考文献：
  名称：

  The Synthesis and Property of Liquid Crystalline 4-Alkoxyl-4″-Cyano-p-Terphenyls

  摘要：

  The synthesis of some new 4-alkoxyl-4 "-cyano-p-terphenyls is described. The preliminary characterization by means of polarized optical microscopy, differential scanning calorimetry and X-ray diffraction shows that all these compounds are thermotropically liquid-crystalline and can form both the nematic and smectic mesophases.

  DOI：

  10.1080/10587250008031039
• 作为产物：
  描述：

  4-乙酰氧基联苯 在 sodium hydroxide 、 溴 、 sodium carbonate 作用下， 以 乙醇 、 水 、 1,2-二氯乙烷 为溶剂， 反应 6.0h， 生成 1-溴-4-(4-乙氧基苯基)苯
  参考文献：
  名称：

  The Synthesis and Property of Liquid Crystalline 4-Alkoxyl-4″-Cyano-p-Terphenyls

  摘要：

  The synthesis of some new 4-alkoxyl-4 "-cyano-p-terphenyls is described. The preliminary characterization by means of polarized optical microscopy, differential scanning calorimetry and X-ray diffraction shows that all these compounds are thermotropically liquid-crystalline and can form both the nematic and smectic mesophases.

  DOI：

  10.1080/10587250008031039

文献信息

• SOLUBLE GUANYLATE CYCLASE ACTIVATORS
  申请人：Bittner Amy R.

  公开号：US20090209556A1

  公开（公告）日：2009-08-20

  A compound having the structure useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, angina pectoris, thromboses, restenoses, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver in a human or animal patient.

  具有治疗或预防心血管疾病、内皮功能障碍、舒张功能障碍、动脉硬化、高血压、心绞痛、血栓形成、再狭窄、心肌梗死、中风、心脏衰竭、肺动脉高压、勃起功能障碍、支气管哮喘、慢性肾功能不全、糖尿病或人或动物患者肝硬化的化合物的结构。
• New compounds, pharmaceutical compositions and uses thereof
  申请人：ROTH Gerald Juergen

  公开号：US20120214782A1

  公开（公告）日：2012-08-23

  The invention relates to new compounds of the formula I to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

  这项发明涉及公式I的新化合物，以及它们作为药物的用途，它们的治疗用途的方法，以及含有它们的药物组合物。
• Substituted cycloalkanecarboxylic acid derivatives as matrix
  申请人：Bayer Corporation

  公开号：US05886022A1

  公开（公告）日：1999-03-23

  Inhibitors for matrix metalloproteases, pharmaceutical compositions containing them, and a process for using them to treat a variety of physiological conditions. The compounds of the invention have the generalized formula ##STR1## wherein each T is a substituent g roup; x is 0, 1, or 2; the group D represents ##STR2## the subscript "e" is 2 or 3; the group R.sup.14 represents a variety of possible substituent groups of the cycloalkyl ring between D and G; the subscript "k" is 0-2; and the group G represents M, ##STR3## in which M represents --CO.sub.2 H, --CON(R.sup.11).sub.2, or --CO.sub.2 R.sup.12 ; and R.sup.13 represents any of the side chains of the 19 noncyclic occurring amino acids.

  抑制基质金属蛋白酶的抑制剂，含有它们的药物组合物，以及使用它们治疗各种生理状况的方法。该发明的化合物具有一般化学式##STR1##其中每个T是一个取代基团；x为0、1或2；D代表##STR2##下标"e"为2或3；R.sup.14代表D和G之间的环烷基环上可能的各种取代基团；下标"k"为0-2；G代表M，##STR3##其中M代表--CO.sub.2 H，--CON(R.sup.11).sub.2，或--CO.sub.2 R.sup.12；R.sup.13代表19种非环状氨基酸的任何一个侧链。
• Selective Suzuki-Miyaura Monocouplings with Symmetrical Dibromoarenes and Aryl Ditriflates for the One-Pot Synthesis of Unsymmetrical Triaryls
  作者：Corinne Minard、Carole Palacio、Kevin Cariou、Robert H. Dodd

  DOI：10.1002/ejoc.201400090

  日期：2014.5

  parameters that would permit selective Suzuki–Miyaura monocouplings of symmetrical dihaloarenes were studied. High selectivity and efficiency can be obtained for a broad range of substrates by using operationally simple conditions and widely available reagents. The 38 different examples described provide a valuable toolbox for the rapid access to unsymmetrical triaryls, as illustrated by the preparation

  研究了允许对称二卤芳烃选择性 Suzuki-Miyaura 单偶联的各种参数。通过使用操作简单的条件和广泛可用的试剂，可以获得对广泛底物的高选择性和效率。所描述的 38 个不同的例子为快速获取不对称三芳基提供了一个有价值的工具箱，如二芳基吡啶 8、三联苯 9 和二芳基吡咯 10 的制备所示。
• Biphenyl quinuclidines
  申请人：Zeneca Limited

  公开号：US05792777A1

  公开（公告）日：1998-08-11

  Biphenylylquinuclidine compounds of the formula I: ##STR1## and pharmaceutically-acceptable salts thereof; wherein R.sup.1 is hydrogen or hydroxy; R.sup.2 is hydrogen; or R.sup.1 and R.sup.2 are joined together so that CR.sup.1 -CR.sup.2 is a double bond; and one or both ring A and ring B may be optionally unsubstituted or independently substituted by one or more substituents selected from halogeno, hydroxy, amino, nitro, cyano, carboxy, carbamoyl, (1-6C)alkyl, (1-6C)alkoxy, (1-6C)alkylamino, di-\x9b(1-6C)alkyl!amino, N-\x9b(1-6C)alkyl!carbamoyl, N,N-di-\x9b(1-6C)alkyl!carbamoyl, (1-6C)alkoxycarbonyl, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl and halogeno-(1-6C)alkyl; are inhibitors of squalene synthase and are hence useful in treating diseases or medical conditions such as hypercholesterolemia, atherosclerosis and fungal diseases. Methods of using these compounds to treat such conditions, novel compounds, processes for making these compounds and pharmaceutical compositions containing them are claimed.

  苯基喹啉化合物的化学式 I：##STR1## 及其药用可接受的盐；其中 R.sup.1 为氢或羟基；R.sup.2 为氢；或 R.sup.1 和 R.sup.2 结合在一起，使得 CR.sup.1 -CR.sup.2 为双键；环 A 和/或环 B 可能是未取代的，也可以独立地被一个或多个卤素、羟基、氨基、硝基、氰基、羧基、氨甲酰基、(1-6C)烷基、(1-6C)烷氧基、(1-6C)烷基氨基、二-(1-6C)烷基氨基、N-(1-6C)烷基)氨甲酰基、N,N-二-(1-6C)烷基)氨甲酰基、(1-6C)烷氧羰基、(1-6C)烷基硫醚基、(1-6C)烷基磺氧基、(1-6C)烷基磺酰基和卤素-(1-6C)烷基取代；这些化合物是角鲨烯合成酶的抑制剂，因此在治疗高胆固醇血症、动脉粥样硬化和真菌病等疾病或医疗状况中有用。声明了使用这些化合物治疗这些疾病的方法、新化合物、制备这些化合物的方法以及含有它们的药物组合物。